Efficacy of Tolvaptan in acute heart failure patients with preserved left ventricular ejection fraction

Trial Profile

Efficacy of Tolvaptan in acute heart failure patients with preserved left ventricular ejection fraction

Completed
Phase of Trial: Phase IV

Latest Information Update: 16 Feb 2017

At a glance

  • Drugs Tolvaptan (Primary)
  • Indications Cardiac oedema; Heart failure
  • Focus Therapeutic Use
  • Most Recent Events

    • 16 Feb 2017 Primary endpoint (Incidence of worsening renal function (WRF)) has been met, according to the article published in the Circulation Journal.
    • 16 Feb 2017 Status changed from recruiting to completed based on the results published in the Circulation Journal.
    • 16 Feb 2017 Results published in the Circulation Journal.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top